EUVIMEDEUVIMED entdecken
Crossref

Pharmacokinetic Study of Fingolimod Nasal Films Administered via Nose-to-Brain Route in C57BL/6 J Mice as Potential Treatment for Multiple Sclerosis

Paraskevi Papakyriakopoulou, Evangelos Balafas, Nikolaos Kostomitsopoulos, Dimitrios M Rekkas, Kumlesh K Dev, Georgia Valsami

Pharmaceutical Research · 2024-10 · 41 (10) · 1951-1963

DOI: 10.1007/s11095-024-03745-8 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pharmaceutical Research, online erschienen am 29.10.2024. Verfasst von Paraskevi Papakyriakopoulou und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, School of Health Sciences Sector of Pharmaceutical Technology, National and Kapodistrian University of Athens, Athens, 15784,…. Hauptthemen laut MEDLINE: Fingolimod Hydrochloride, Administration, Intranasal, Mice, Inbred C57BL, Multiple Sclerosis. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 44 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Fingolimod hydrochloride (FH) has emerged as a vital medication for managing Multiple Sclerosis (MS). Despite its high oral bioavailability of 93%, it is plagued by slow oral absorption (Tmax = 8-12 h) and extensive hepatic metabolism. Intranasal administration has emerged as an alternative to address these limitations, ensuring efficient central nervous system delivery and minimizing peripheral exposure and first-pass metabolism. OBJECTIVE: This study aims to develop and evaluate FH nasal films for enhanced drug delivery. METHODS: A Design of Experiments approach was employed to formulate FH nasal films, utilizing HPMC E50 as a film-forming polymer, PEG 400 as a plasticizer, and Me-β-CD as a permeation enhancer. Two formulations with superior in vitro and ex vivo performance were selected for in vivo evaluation. A comparative pharmacokinetic study was conducted in C57BL/6 J mice in the brain and serum after administration of nasal films and oral FH solution, respectively. Sparse sampling and non-compartmental analysis were used. RESULTS: FH nasal films efficiently delivered the drug to both serum (Cmax(F3) = 0.35 ± 0.021, Cmax(F4) = 0.38 ± 0.029 μg/mL) and brain (Cmax(F3) = 0.39 ± 0.05, Cmax(F4) = 0.44 ± 0.048 μg/mL), achieving higher levels than oral delivery. Brain relative bioavailability (% Frel (0-6 h)) was 519% and 534%, while serum % Frel (0-6 h) was 295% and 343%. CONCLUSIONS: The rapid nose-to-brain delivery within 30 min, in contrast to 10-h Tmax of the oral solution, indicates the potential of a combined IN and oral treatment regimen. This approach could expedite the attainment of steady-state concentrations, offering a promising method for managing multiple sclerosis (MS).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Fingolimod HydrochlorideAdministration, IntranasalMice, Inbred C57BLMultiple SclerosisBrainAnimalsMiceBiological AvailabilityImmunosuppressive AgentsNasal MucosaDrug Delivery SystemsAdministration, OralMaleFemale

Stichwörter der Autor:innen

fingolimodmultiple sclerosisnasal filmnose-to-brainpharmacokinetic study

Substanzen

Fingolimod HydrochlorideImmunosuppressive Agents

Autor:innen und Institutionen

  • Department of Pharmacy, School of Health Sciences Sector of Pharmaceutical Technology, National and Kapodistrian University of Athens, Athens, 15784, Greece.
  • Laboratory Animal Facility, Centre of Clinical, Experimental Surgery and Translational Research, Biomedical Research Foundation of the Academy of Athens, Athens, 11527, Greece.
  • Department of Physiology, Drug Development Research Group, School of Medicine, Trinity College Dublin, Dublin, D18 DH50, Ireland. devk@tcd.ie.
  • Department of Pharmacy, School of Health Sciences Sector of Pharmaceutical Technology, National and Kapodistrian University of Athens, Athens, 15784, Greece. valsami@pharm.uoa.gr.

Zitieren

APA

Papakyriakopoulou, P., Balafas, E., Kostomitsopoulos, N., Rekkas, D. M., Dev, K. K., & Valsami, G. (2024). Pharmacokinetic Study of Fingolimod Nasal Films Administered via Nose-to-Brain Route in C57BL/6 J Mice as Potential Treatment for Multiple Sclerosis. Pharmaceutical Research, 41(10), 1951-1963. https://doi.org/10.1007/s11095-024-03745-8

Vancouver

Papakyriakopoulou P, Balafas E, Kostomitsopoulos N, Rekkas DM, Dev KK, Valsami G. Pharmacokinetic Study of Fingolimod Nasal Films Administered via Nose-to-Brain Route in C57BL/6 J Mice as Potential Treatment for Multiple Sclerosis. Pharmaceutical Research. 2024;41(10):1951-1963. doi:10.1007/s11095-024-03745-8

BibTeX
@article{Papakyriakopoulou2024,
  author = {Papakyriakopoulou, Paraskevi and Balafas, Evangelos and Kostomitsopoulos, Nikolaos and Rekkas, Dimitrios M and Dev, Kumlesh K and Valsami, Georgia},
  title = {Pharmacokinetic Study of Fingolimod Nasal Films Administered via Nose-to-Brain Route in C57BL/6 J Mice as Potential Treatment for Multiple Sclerosis},
  journal = {Pharmaceutical Research},
  year = {2024},
  volume = {41},
  number = {10},
  pages = {1951--1963},
  doi = {10.1007/s11095-024-03745-8}
}
Kostenlos starten →